Arcturus Therapeutics (ARCT) News Today

Arcturus Therapeutics Holdings Inc. (ARCT) — Shares are trading lower overall after interim Phase 2 cystic fibrosis (CF) data released last week were widely viewed as mixed/underwhelming and triggered a sharp selloff. The decline prompted multiple analyst rating changes and steep cuts to price targets; however, a few firms remain constructive at reduced targets. Below are the items most likely driving today's action.

• Positive Sentiment: BTIG cut its price target from $48 to $23 but kept a "buy" rating, signaling some analysts still see multi‑month upside despite the weak data. BTIG Research Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price
• Positive Sentiment: Wells Fargo lowered its target from $42 to $20 but maintained an "overweight" rating, implying the stock still has meaningful upside from current levels in their view. Arcturus Therapeutics (NASDAQ:ARCT) Given New $20.00 Price Target at Wells Fargo & Company
• Neutral Sentiment: Coverage pieces are framing the situation as a pivotal reset for Arcturus: some view the CF readout as a setback that re-writes the story, while others are parsing subgroup and safety data for salvageable value. How Recent Shifts Are Rewriting the Story for Arcturus Therapeutics Holdings
• Negative Sentiment: Arcturus released interim Phase 2 data for its mRNA‑tied CF program that investors judged mixed/underwhelming, the primary catalyst for the ensuing selloff. Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
• Negative Sentiment: Following the readout, shares plunged sharply in after‑hours/early trading on Oct. 22 — headlines report declines of ~50%+, signaling heavy liquidation and sentiment deterioration. Arcturus Shares Plunge After Midstage Trial Data
• Negative Sentiment: Multiple brokers downgraded or cut targets: Guggenheim moved ARCT to neutral, and Citigroup downgraded to neutral and cut its target to $12 — both actions increase near‑term selling pressure. Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Neutral Rating by Guggenheim Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Citigroup

Bottom line for investors: the CF Phase 2 readout is the proximate cause of the selloff and analyst re‑ratings. Watch for company commentary, full data release and any guidance on next steps; those items will determine whether the remaining bullish analyst views (at reduced targets) can stabilize the stock.